Clinical uses of plasma and plasma fractions: Plasma-derived products for hemophilias A and B, and for von Willebrand disease

Best Practice and Research: Clinical Haematology

Volumn 19, Issue 1, 2006, Pages 35-49

  Josephson, Cassandra D ^a,b   Abshire, Thomas C ^b,c  

^a CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Penn Comprehensive Hemophilia and Thrombosis Program   (United States)

Author keywords

Hemophilia treatment; Plasma derived factor products; Viral attenuation

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; ALPHANATE SD; ALPHANINE SD; AUTOPLEX T; BEBULIN VH; BIOSTATE; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9 COMPLEX; BLOOD CLOTTING FACTOR 9 CONCENTRATE; BLOOD CLOTTING FACTOR 9A; BLOOD CLOTTING FACTOR CONCENTRATE; DESMOPRESSIN ACETATE; FEIBA VH; FRESH FROZEN PLASMA; IMMUNOGLOBULIN; KOATE DVI; KONYNE 80; MONARC M; PROFILNINE SD; PROPLEX T; PROTHROMBIN; PROTHROMBIN A; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9; VON WILLEBRAND FACTOR; WILFACTIN;

ANAPHYLAXIS; DEVELOPING COUNTRY; DRUG EFFICACY; DRUG SAFETY; HEMOPHILIA A; HEMOPHILIA B; HEPATITIS C; HUMAN; MEDICAL DECISION MAKING; NEPHROTIC SYNDROME; PRIORITY JOURNAL; REVIEW; SUBSTITUTION THERAPY; TREATMENT PLANNING; VIRUS ATTENUATION; VON WILLEBRAND DISEASE;

BLOOD COAGULATION FACTORS; HEMOPHILIA A; HEMOPHILIA B; HUMANS; PLASMA; VON WILLEBRAND DISEASE;

EID: 31044447908     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2005.01.031     Document Type: Review

References (75)

1. K. Schimpf On the way to virus-safe blood coagulation factor concentrates Semin Thromb Haemost 28 2002 15-24
2. J.J. Toole J.L. Knopf J.M. Wozney L.A. Sultzman et al. Molecular cloning of a cDNA encoding human antihaemophilic factor Nature 312 1984 342-347
3. K.H. Choo K.G. Gould D.J. Rees & G.G. Brownlee Molecular cloning of the gene for human anti-haemophilic factor IX Nature 299 5879 1982 178-180
4. C. Rothschild et al. J Thromb Hemost Suppl 2003 abstrOC215
5. G. Auerswald Th Spranger H.H. Brackmann & The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A Haematologica 88 2003 21-29
6. M.C. Poon L.M. Aledort K. Anderle et al. Comparison of the recovery and half-life of a high purity factor IX concentrate with those of a factor IX complex concentrate. Factor IX Study Group Transfusion 35 1995 319-323
7. K. Kavakli A. Gringeri R. Bader et al. Inhibitor development and substitution therapy in a developing country: Turkey Haemophilia 4 1998 104-108
8. A. Srivastava Choice of factor concentrates for haemophilia: A developing world perspective Haemophilia 7 2001 117-122
9. J.M. Lusher Hemophilia A and B in: J. Lilleyman I. Hann & V. Blanchette (eds) Pedeatric Hematology 2nd edn 1999 Churchill Livingstone London, UK 585-600
10. R.D. Bona R.A. Weinstein S.T. Weisman et al. The use of continuous infusion of factor concentrates in the treatment of hemophilia Am J Hematol 1990
11. S. Lane Successful transfusion of blood Lancet 1 1840 185-188
12. J.G. Pool E.J. Gershgold & A.R. Pappenhagen High-potency antihaemophilic factor concentrate prepared from cryoglobulin precipitate Nature 18 203 1964 312
13. M.W. Hilgartner The need for recombinant factor VIII: Historical background and rationale Semin Hematol 28 supplement 1 1991 6-9
14. W.K. Hoots History of plasma-product safety Transfus Med Rev 15 2001 3-10
15. C.K. Kasper & J.M. Lusher Recent evolution of clotting factor concentrates for hemophilia A and B. Transfusion Practices Committee Transfusion 33 1993 422-434
16. A. Farrugia Evolving perspectives in product safety for haemophilia Haemophilia 8 2002 236-243
17. Accredo Health Inc. Announces Record Results; Third Quarter Earnings Increase 75%. Accessed 5-2-2004 at http://www.accredohealth.net/ahi/news/ pr010430.html
18. Factor VIII Product Shortage. World Federation of Hemophilia Information Update. 2001. Accessed on 4-2-04. at http://www.wfh.org/ Content_Documents/Newsletters/IU_April01_Eng.pdf
19. J.M. Soucie L.C. Richardson B.E. Evatt et al. Risk factors for infection with HBV and HCV in a large cohort of hemophiliac males Transfusion 41 2001 338-343
20. T.L. Chorba R.C. Holman M.J. Clarke et al. Effects of HIV infection on age and cause of death for persons with hemophilia A in the United States Am J Hematol 66 2001 229-240
21. W. Fricke L. Augustyniak D. Lawrence A. Brownstein et al. Human immunodeficiency virus infection due to clotting factor concentrates: results of the Seroconversion Surveillance Project Transfusion 32 1992 707-709
22. A. Groener S. Mehdi W. Schafer & M. Spyra Human parvovirus B19 is inactivated by pasteurization, a dedicated virus reduction step in the manufacturing procedure of plasma derivatives [abstract] Blood 102 2003 4241
23. P.M. Mannucci Treatment of hemophilia: Recombinant factor only? No J Thromb Haemost 1 2003 216-217
24. S. Ehrenforth W. Kreuz I. Scharrer et al. Incidence of factor VIII and factor IX inhibitors in hemophiliacs Lancet 339 1992 594-598
25. J.M. Lusher Is the incidence and prevalence of inhibitors great with recombinant products? No J Thromb Heamost 2 2004 863-865
26. L.M. Aledort Is the incidence and prevalence of inhibitors greater with recombinant products? Yes J Thromb Heaemost 2 2004 861-862
27. M. Gensana C. Altiesent J.A. Aznar et al. Influence of von Willebrand factor on the reactivity of human factor VIII inhibitors Haemophilia 7 2001 369-374
28. M. Behrmann J. Pasi J.M.R. Saint-Remy et al. Von Willebrand factor modulates factor VIII immunogenicity: Comparative study of different factor VIII concentrates in a hemophilia A mouse model Thromb Haemost 88 2002 221-229
29. A.R. Thompson Structure, function, and molecular defects of factor IX Blood 67 1986 565-672
30. E.J. Hershgold J.G. Pool A.R. Pappenhagen & The potent antihemophilic globulin concentrate derived from a cold insoluble fraction of human plasma: Characterization and further data on preparation and clinical trial J Lab Clin Med 67 1966 23-32
31. L.M. Aldort Introduction and overview of treatment Semin Hematol 28 1991 1-2
32. J.M. Lusher Thrombogenicity associated with factor IX complex concentrates Semin Hematol 28 1991 3-5
33. E.W. Campbell S. Neff & A.J. Bowdler Therapy with factor IX concentrate resulting in DIC and thromboembolic phenomena Transfusion 18 1978 94-97
34. C.K. Kasper Postoperative thromboses in hemophilia B (letter) N Eng J Med 289 1973 160
35. P.M. Blatt R.L. Lundblad H.S. Kingdon et al. Thrombogenic materials in prothrombin complex concentrates Ann Intern Med 81 1974 766-770
36. D. Menache H.E. Behre C.L. Orthner et al. Coagulation factor IX concentrate: Method of preparation and assessment of potential in vivo thrombogenicity in animal models Blood 64 1984 1220-1227
37. C. Julius & R.G. Westphal The safety of blood components and derivatives Hematol Oncol Clin North Am 6 1992 1057-1077
38. P.M. Mannucci K.A. Bauer A. Gringeri et al. Thrombin generation is not increased in the blood of hemophilia B patients aft the infusion of a purified factor IX concentrate Blood 76 1990 2540-2545
39. A.R. Thompson Factor IX concentrates for clinical use Semin Thromb Hemost 19 1993 25-36
40. E. Berntorp S. Bjorkman M. Carlsson et al. Biochemical and in vivo properties of high purity factor IX concentrates Thromb Haemost 70 1993 768-773
41. Abshire T, Shapiro A, Gill J et al. Recombinant FIX (rFIX) in the treatment of previously untreated patients with severe or moderately severe hemophilia B. Presented at XXIII International Congress of the World Federation of Haemophilia, The Hague, The Netherlands; 1998.
42. E. Tabor The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1 Transfusion 39 1999 1160-1168
43. H.K. Future B. Horowitz R. Bonomo et al. Solvent/detergent treated plasma: A virus substitute for fresh frozen plasma Blood 79 1992 826-831
44. M. Hilgartner L. Aledort A. Andes & J. Gill Efficacy and safety of vapor-heated anti-inhibitor complex in hemophilia patients. FEIBA Study Group Transfusion 30 1990 626-630
45. A.D. Shapiro M.V. Ragni J.M. Lusher et al. Safety and efficacy of monoclonal antibody purified factor IX concentrate in previously untreated patients with hemophilia B Thromb Haemost 75 1996 30
46. N.P. Zauber J. Levin et al. Factor IX level in patients with hemophilia B (Christmas disease) following transfusion with concentrates of factor IX fresh frozen plasma Medicine 56 1977 213-224
47. E. Berntorp S. Bjorkman M. Carrlson et al. Biochemical and in vivo properties of high purity factor IX concentrates Thromb Haemost 70 1993 768-773
48. M.C. Poon L.M. Aledort K. Anderle et al. Comparison of the recovery and half-life of a high purity factor IX concentrate with those of a factor IX complex concentrate. Factor IX Study Group Transfusion 35 1995 319-323
49. J.C. Goldsmith C.K. Kasper P.M. Blatt et al. Coagulation factor IX. Successful surgical experience with purified factor IX concentrate Am J Hematol 40 1992 210-215
50. W.K. Hoots The future of plasma-derived clotting factor concentrates Haemophilia 7 2001 4-9
51. C.T. Kisker A. Eisberg & B. Schwartz Mononine Study Group Prophylaxis in factor IX deficiency product and patient variation Haemophilia 9 2003 279-284
52. I. Warrier B.M. Ewenstein M.A. Koerper et al. Factor IX inhibitors and anaphylaxis in hemophilia B J Pediatr Hematol Oncol 19 1997 23-27
53. P. Mathew & C. Altisent Recombinant versus plasma-derived factor IX in the treatment of hemophilia B: Proceedings of a meeting held in June 2003 Blood Coagul Fibrin 15 2004 S1-S3
54. F. Rodeghiero G. Castaman & E. Dini Epidemiological investigation of the prevalence of von Willebrand disease Blood 69 1987 454-459
55. E.J. Werner E.H. Boxson E.L. Tucker et al. Prevalence of von Willebrand disease in children: A multi-ethnic study J Pediatr 123 1993 893-898
56. J.P. Scott & R.R. Montgomery Therapy of von Willlebrand disease Semin Thromb Hemost 19 1993 37-47
57. H.J. Weiss I.I. Sussman & L.W. Hoyer Stabilization of factor VIII in plasma by the von Willebrand factor: Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's Disease J Clin Invest 60 1977 390-404
58. Manuucci PM. Treatment of von Willebrand's Disease. N Engl J Med 351;7:683-94.
59. J.E. Sadler A revised classification of von Willebrand disease Thromb Haemost 71 1994 520-525
60. Holmberg L, & Nilsson IM. von Willebrand's Disease. Eur J Haematol 192;48:127-41.
61. H.A. Perkins Correction of the hemostatic defects in von Willebrand's Disease Blood 30 1967 375-380
62. C.J. Gill B.M. Ewenstein A.R. Thompson et al. Successful treatment of urgent bleeding in von Willebrand disease with FVIII/VWF concentrate (Humate-P): Use of ristocetin factor assay (VWF:RCo) to measure potency and to guide therapy Haemophilia 9 2003 688-695
63. A.R. Thompson J.C. Gill B.M. Ewenstein et al. Successful treatment for patients with von Willebrand disease undergoing urgent surgery using factor VIII/VWF concentrate (Humate-P) Haemophilia 10 2004 42-51
64. P.M. Mannucci j. Chediak W. Hanna et al. Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: A prospective, multicenter study Blood 99 2002 450-456
65. C.K. Kasper Von Willebrand Disease Primer Aventis Behring Foundation for Research and Advancement of Patient Health 2004 p. 1-58
66. K. Schimpf H.H. Brackmann W. Kreuz et al. Absence of anti-human immunodeficiency virus type I and 2 seroconversion after the treatment of hemophilia and von Willebrand disease with pasteurized factor VIII concentrate N Engl J Med 26 321 1989 1148-1152
67. C. Mazurier C. De Romeuf A. Parquet-Gernez & M. Goudemand In vitro and in vivo characterization of a high-purity solvent/detergent-treated factor VIII concentrate: Evidence for its therapeutic efficacy in von Willebrand disease Eur J Haematol 43 1989 7-14
68. P. Turecek H. Gritsch L. Pichler et al. In vivo characterization of recombinant von Willebrand factor in dogs with von Willebrand disease Blood 90 1997 3555-3567
69. K. Schimpf P.M. Mannucci W. Kreutz et al. Absence of hepatitis after treatment with a pasteurized factor VIII concentrate in patients with hemophilia and no previous transfusions N Eng J Med 316 1987 918-922
70. P.M. Mannucci J. Chediak W. Hanna et al. Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: A prospective, multicenter study Blood 99 2002 450-456
71. W.T. Hanna R.D. Bona C.E. Zimmerman et al. The use of intermediate and high purity factor VIII products in the treatment of von Willebrand disease Thromb Haemost 71 1994 173-179
72. E.J. Favaloro M. Bukuva T. Martinelli et al. A comparative mulit-laboratory assessment of three factor VIII/von Willebrand factor concentrates Thromb Haemost 87 2002 466-476
73. J. Goudemand C. Mazurier A. Marey et al. Clinical and biological evaluation in von Willebrand's disease of a von Willebrand factor concentrate wit low factor VIII activity Br J Haematol 80 1992 21-221
74. J. Goudemand C. Negrier N. Onnoughene & Y. Sultan Clinical management of patients with von Willebrand's disease with VHP VWF concentrate: The French experience Haemophilia 4 1998 48-52
75. Aventis Behring. Humate-P package insert; July, 2000.